HOPE-Sepsis: Hemoadsorption Therapy for Sepsis
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 30 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional
- Treatments tested
- Hemoperfusion with CA330 Cytokine Adsorption Column
- Record updated
- 8 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age ≥18 years. Sepsis (Sepsis-3): Diagnosis of sepsis according to Sepsis-3 criteria. Blood IL-6 >100 pg/mL, Expected ICU stay >48 hours. Informed consent obtained from the patient or legally authorized representative
Who cannot take part
- Immunosuppressed state, such as receiving immunosuppressive therapy or HIV infection
- Pre-existing chronic kidney disease or end-stage renal disease. Pregnancy or lactation. Refusal to participate in the study
- Severe coagulation dysfunction, including platelet count <50 × 10⁹/L or significantly prolonged PT/APTT
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-center, prospective, single-arm, open-label study that will enroll 30 adult patients with sepsis at Zhongshan Hospital, Fudan University. All participants will receive CA330 hemoadsorption in addition to standard care. Blood samples will be collected at prespecified time points before hemoadsorption (T0), immediately after completion of hemoadsorption (T1), and approximately 24 hours after completion of hemoadsorption (T2) to evaluate changes in IL-6 and other inflammatory biomarkers. TMT-based quantitative proteomics will be performed on plasma samples collected at T0 and T1 to characterize acute treatment-associated molecular changes and explore their relationships with clinical outcomes.
The group in the trial
- Hemoadsorption ArmTreatment being tested
Participants will receive CA330 hemoadsorption in addition to standard care for sepsis. Blood samples will be collected at T0 (before hemoadsorption), T1 (immediately after completion of hemoadsorption), and T2 (24 ±2 hours after treatment) for biomarker assessment. Plasma proteomics will be performed using samples collected at T0 and T1.
Treatment: Hemoperfusion with CA330 Cytokine Adsorption Column
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Proteomic Analysis and Clinical Efficacy Evaluation of Hemoadsorption Therapy in Sepsis
- Record updated
- 8 October 2026